Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...
Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The ...
Eli Lilly and Company (LLY) is a global pharmaceutical leader focused on discovering, developing, and commercializing ...
Eli Lilly 's ( LLY +1.58%) share price has soared over the past five years (up 530%). In fact, it's hard to find a single ...
Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.
In a significant move to address supply constraints, Eli Lilly announced a $6 billion investment to construct a new manufacturing facility in Huntsville, Alabama. This site is slated to produce both ...
Clinical Trials Arena on MSN
Lilly’s triple G agonist boasts 28.7% weight loss in Phase III trial
Lilly is investigating the triple G agonist retatrutide in seven other Phase III trials, which are due to read out in 2026.
US pharma major Eli Lilly (NYSE: LLY) has lowered the price of Zepbound (tirzepatide) single-dose vials on its Lilly Direct ...
In the last decade, Eli Lilly stock (NYSE: LLY) has returned $47 billion to its shareholders via dividends and buybacks. This shareholder-centric approach has delivered solid results in 2025, with the ...
Eli Lilly and Company (NYSE:LLY) is included among the 14 Best US Stocks to Buy for Long Term. On December 3, Guggenheim ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback